Navigation Links
NBTY Reports Second Quarter Results
Date:4/24/2008

RONKONKOMA, N.Y., April 24 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (http://www.NBTY.com), a leading global manufacturer and marketer of nutritional supplements, today announced results for the fiscal second quarter and first six months ended March 31, 2008.

For the fiscal second quarter ended March 31, 2008, net sales were $533 million compared to $508 million for the fiscal second quarter ended March 31, 2007, an increase of $24 million or 5%.

Net income for the fiscal second quarter ended March 31, 2008 was $44 million, or $0.67 per diluted share, compared to $57 million, or $0.83 per diluted share, for the fiscal second quarter ended March 31, 2007. The decrease in net income reflects the decrease in overall gross profit from 53% to 51% and higher advertising and selling, general and administrative costs incurred in the fiscal second quarter.

Adjusted EBITDA for the fiscal second quarter ended March 31, 2008 was $84 million compared to $100 million for the prior like quarter. At March 31, 2008, NBTY had total assets of $1.5 billion and working capital of $494 million. The Company is committed to using its cash and leverage to increase shareholder value through investments in infrastructure, opportunistic acquisitions and stock repurchases. During the quarter, $8 million in short term municipal auction rate securities were reclassified into Other Assets to reflect the lack of liquidity.

Net sales for the six months ended March 31, 2008 increased 3% to $1.043 billion.

Net income for the six months ended March 31, 2008 was $90 million, or $1.34 per diluted share, compared to $108 million, or $1.56 per diluted share, for the six months ended March 31, 2007. The decrease in net income reflects higher advertising and SG&A costs.

Adjusted EBITDA for the six months ended March 31, 2008 was $171 million compared to $196 million for the six months ended March 31, 2007. For the six months

ended March 31,

2008 2007

Net sales $1,043,376 $1,014,697

Costs and expenses:

Cost of sales 501,615 486,578

Advertising, promotion and catalog 73,176 61,204

Selling, general and administrative 334,531 303,902

909,322 851,684

Income from operations 134,054 163,013

Other income (expense):

Interest (7,519) (9,217)

Miscellaneous, net 8,673 3,646

1,154 (5,571)

Income before provision for income taxes 135,208 157,442

Provision for income taxes 45,160 49,232

Net income $90,048 $108,210

Net income per share:

Basic $1.37 $1.61

Diluted $1.34 $1.56

Weighted average common shares outstanding:

Basic 65,510 67,242

Diluted 67,313 69,423

SALES

(Unaudited)

THREE MONTHS ENDED

MARCH 31,

Percentage

(In thousands) 2008 2007 Change

Wholesale / US Nutrition $259,363 $244,968 6%

North American Retail 51,904 55,764 -7%

European Retail 158,070 159,554 -1%

Direct Response / E-Commerce 63,181 48,173 31%

Total $532,518 $508,459 5%

GROSS PROFIT

PERCENTAGES

(Unaudited)

THREE MONTHS ENDED

MARCH 31,

Increase

2008 2007 - Decrease

Wholesale / US Nutrition 41% 43% -2%

North American Retail 62% 60% 2%

European Retail 61% 64% -3%

Direct Response / E-Commerce 59% 61% -2%

Total 51% 53% -2%

SALES

(Unaudited)

SIX MONTHS ENDED

MARCH 31,

Percentage

(In thousands) 2008 2007 Change

Wholesale / US Nutrition $518,298 $491,697 5%

North American Retail 108,086 110,737 -2%

European Retail 316,666 312,520 1%

Direct Response / E-Commerce 100,326 99,743 1%

Total $1,043,376 $1,014,697 3%

GROSS PROFIT

PERCENTAGES

(Unaudited)

SIX MONTHS ENDED

MARCH 31,

Increase

2008 2007 - Decrease

Wholesale / US Nutrition 42% 41% 1%

North American Retail 60% 60% 0%

European Retail 62% 64% -2%

Direct Response / E-Commerce 60% 61% -1%

Total 52% 52% 0%

ADJUSTED EBITDA**

Reconciliation of GAAP Measures to Non-GAAP Measures

(Unaudited)

(In thousands)

THREE MONTHS ENDED

MARCH 31, 2008

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale / US

Nutrition $41,507 $2,578 $- $48 $44,133

North American

Retail 522 804 - 16 1,342

European Retail 34,266 2,970 - 41 37,277

Direct Response /

E-Commerce 15,750 1,374 - 20 17,144

Segment Results 92,045 7,726 - 125 99,896

Corporate /

Manufacturing (26,098) 5,998 3,657 393 (16,050)

Total $65,947 $13,724 $3,657 $518 $83,846

THREE MONTHS ENDED

MARCH 31, 2007

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale / US

Nutrition $48,748 $2,770 $- $- $51,518

North American

Retail 984 997 - 231 2,212

European Retail 43,705 2,737 - - 46,442

Direct Response /

E-Commerce 12,498 1,263 - - 13,761

Segment Results 105,935 7,767 - 231 113,933

Corporate /

Manufacturing (25,257) 6,747 4,154 - (14,356)

Total $80,678 $14,514 $4,154 $231 $99,577

** SINCE ADJUSTED EBITDA IS NOT A MEASURE OF PERFORMANCE CALCULATED IN

ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES ("GAAP"), IT

SHOULD NOT BE CONSIDERED IN ISOLATION OF, OR AS A SUBSTITUTE FOR OR

SUPERIOR TO, OTHER MEASURES OF FINANCIAL PERFORMANCE PREPARED IN

ACCORDANCE WITH GAAP, SUCH AS OPERATING INCOME, NET INCOME AND CASH FLOWS

FROM OPERATING ACTIVITIES. IN ADDITION, THE COMPANY'S DEFINITION OF

ADJUSTED EBITDA IS NOT NECESSARILY COMPARABLE TO SIMILARLY TITLED MEASURES

REPORTED BY OTHER COMPANIES.

ADJUSTED EBITDA**

Reconciliation of GAAP Measures to Non-GAAP Measures

(Unaudited)

(In thousands)

SIX MONTHS ENDED

MARCH 31, 2008

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale / US

Nutrition $95,488 $5,272 $- $48 $100,808

North American

Retail (342) 1,654 - 366 1,678

European Retail 69,333 6,032 - 41 75,406

Direct Response /

E-Commerce 22,872 2,740 - 20 25,632

Segment Results 187,351 15,698 - 475 203,524

Corporate /

Manufacturing (52,143) 11,957 7,519 393 (32,274)

Total $135,208 $27,655 $7,519 $868 $171,250

SIX MONTHS ENDED

MARCH 31, 2007

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale / US

Nutrition $98,337 $5,559 $- $- $103,896

North American

Retail 2,071 2,134 - 584 4,789

European Retail 82,529 5,565 - - 88,094

Direct Response /

E-Commerce 28,091 2,528 - - 30,619

Segment Results 211,028 15,786 - 584 227,398

Corporate /

Manufacturing (53,586) 12,960 9,217 - (31,409)

Total $157,442 $28,746 $9,217 $584 $195,989

** SINCE ADJUSTED EBITDA IS NOT A MEASURE OF PERFORMANCE CALCULATED IN

ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES ("GAAP"), IT

SHOULD NOT BE CONSIDERED IN ISOLATION OF, OR AS A SUBSTITUTE FOR OR

SUPERIOR TO, OTHER MEASURES OF FINANCIAL PERFORMANCE PREPARED IN

ACCORDANCE WITH GAAP, SUCH AS OPERATING INCOME, NET INCOME AND CASH FLOWS

FROM OPERATING ACTIVITIES. IN ADDITION, THE COMPANY'S DEFINITION OF

ADJUSTED EBITDA IS NOT NECESSARILY COMPARABLE TO SIMILARLY TITLED MEASURES

REPORTED BY OTHER COMPANIES.

NBTY, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(Dollars and shares in thousands, except per share amounts)

March 31, September 30,

2008 2007

Current assets:

Cash and cash equivalents $104,908 $92,902

Investments 24,991 121,382

Accounts receivable, net 99,725 98,454

Inventories 389,474 384,990

Deferred income taxes 21,855 21,441

Prepaid expenses and other

current assets 49,291 54,460

Total current assets 690,244 773,629

Property, plant and equipment, net 321,555 323,154

Goodwill 249,811 251,753

Intangible assets, net 154,763 157,548

Other assets 36,674 28,851

Total assets $1,453,047 $1,534,935

Current liabilities:

Current portion of long-term debt $972 $989

Accounts payable 86,363 71,852

Accrued expenses and other

current liabilities 109,121 125,533

Total current liabilities 196,456 198,374

Long-term debt, net of current

portion 209,164 210,106

Deferred income taxes 58,613 61,788

Other liabilities 11,802 8,697

Total liabilities 476,035 478,965

Commitments and contingencies

Stockholders' equity:

Common stock, $0.008 par; authorized 175,000

shares; issued and outstanding 61,637

shares at March 31, 2008 and 67,118

shares at September 30, 2007 493 537

Capital in excess of par 141,283 143,244

Retained earnings 792,226 864,852

Accumulated other comprehensive

income 43,010 47,337

Total stockholders' equity 977,012 1,055,970

Total liabilities and stockholders'

equity $1,453,047 $1,534,935

NBTY, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

For the six months

ended March 31,

2008 2007

Cash flows from operating activities:

Net income $90,048 $108,210

Adjustments to reconcile net income to

cash provided by operating activities:

Impairments and disposals of property, plant and

equipment 482 1,112

Depreciation and amortization 27,655 28,746

Foreign currency transaction (gain) loss (1,385) 212

Stock-based compensation 518 -

Amortization and write-off of deferred charges 372 1,515

Allowance for doubtful accounts (174) (384)

Inventory reserves 2,465 4,265

Deferred income taxes 903 7,385

Excess income tax benefit from exercise of stock

options (4,984) (1,884)

Changes in operating assets and liabilities, net

of acquisitions:

Accounts receivable (153) (203)

Inventories (8,156) (19,623)

Prepaid expenses and other current assets 4,849 10,967

Other assets (608) (150)

Accounts payable 13,927 6,807

Accrued expenses and other liabilities (10,946) 5,058

Net cash provided by operating activities 114,813 152,033

Cash flows from investing activities:

Purchase of property, plant and equipment (21,693) (20,880)

Purchase of available-for-sale investments (159,884) (317,050)

Proceeds from sale of available-for-sale

investments 248,728 191,472

Cash paid for acquisitions, net of cash acquired (5,072) (37,005)

Cash collateral securing loan - (18,539)

Net cash provided by (used in) investing

activities 62,079 (202,002)

Cash flows from financing activities:

Principal payments under long-term debt agreements

and capital leases (481) (425)

Payments for financing fees - (1,649)

Excess income tax benefit from exercise of stock

options 4,984 1,884

Proceeds from stock options exercised 3,852 634

Purchase of treasury stock (subsequently retired) (171,008) -

Net cash (used in) provided by financing

activities (162,653) 444

Effect of exchange rate changes on cash and cash

equivalents (2,233) 1,957

Net increase (decrease) in cash and cash equivalents 12,006 (47,568)

Cash and cash equivalents at beginning of the period 92,902 89,805

Cash and cash equivalents at end of the period $104,908 $42,237

In fiscal year 2008, NBTY repurchased a total of 6.1 million shares of its common stock under an existing publicly announced share repurchase program. The Company repurchased 296 thousand shares in October 2007 for approximately $11 million and 5.8 million shares were repurchased in February 2008 for $160 million.

Accordingly, the number of weighted average diluted shares for the quarter ended March 31, 2008 was 66 million and is expected to decline in future quarters to approximately 63 million when reflecting the full impact of the stock repurchase.

OPERATIONS FOR THE FISCAL SECOND QUARTER ENDED MARCH 31, 2008

Net sales for the Wholesale/US Nutrition division, which markets Nature's Bounty, Solgar, Osteo Bi-Flex, Rexall, Ester-C and other brands, increased $14 million or 6% to $259 million from $245 million for the prior like quarter. Gross profit for the Wholesale operation was 41%, compared to 43% for the prior like quarter. The decrease in gross profit reflects changes in product mix and more promotional programs offered to customers. This division continues to gain market share. Information Resources Inc. (IRI) tracks industry-wide sales in the food, drug and mass market sectors. For the thirteen week period ended March 30, 2008, IRI reported an increase in the category of 7%. According to IRI, for the same period, the Company's Wholesale division reported a 23% increase. The Company is encouraged by this increase.

The Wholesale/US Nutrition division utilizes valuable consumer preference sales data generated by the Company's Vitamin World retail stores and Puritan's Pride Direct Response/E-Commerce operations to empower its wholesale customers with this latest data. The Vitamin World stores are used as a laboratory for new ideas and are an effective tool in determining and monitoring consumer preferences. This information, as well as scanned sales data from the Vitamin World stores, is shared on a real time basis with our wholesale customers to give them a competitive advantage.

Net sales for the North American Retail division were $52 million for the fiscal second quarter ended March 31, 2008 compared with $56 million for the prior like quarter. The North American Retail division and Vitamin World were profitable, although LeNaturiste, the Company's Canadian retail chain, operated at a loss.

Same store sales for North American Retail decreased 4% for the fiscal second quarter of 2008. The North American Retail division continues to focus on rationalizing SKUs, enhancing visual merchandising and increasing customer traffic. During the fiscal second quarter of 2008, the North American Retail division closed 7 under-performing stores and added 3 new stores. At the end of the fiscal second quarter, the North American Retail division operated a total of 530 stores consisting of 450 Vitamin World stores in the United States and 80 LeNaturiste stores in Canada. During the remainder of fiscal 2008, North American Retail anticipates opening 7 stores and closing 7 under- performing stores.

European Retail net sales for the fiscal second quarter of 2008 were $158 million compared to $160 million for the prior like period. European Retail division same store sales in local currency decreased 4% reflecting the continued difficult retail environment. The European Retail division consists of 516 Holland & Barrett and 31 GNC stores in the UK, 19 Nature's Way stores in Ireland, and 70 DeTuinen stores in the Netherlands for a total of 636 stores. During the fiscal second quarter of 2008 the European Retail division opened 2 stores. During the remainder of fiscal 2008, the European Retail division anticipates opening 19 additional stores. The European Retail division continues to leverage its premier status, high street locations and brand awareness in a difficult retail environment.

Net sales from Direct Response/E-Commerce operations for the fiscal second quarter of 2008 increased $15 million, or 31% to $63 million from $48 million for the fiscal second quarter of 2007. This division varies its promotional strategy throughout the fiscal year, utilizing highly promotional priced catalogs which are not offered in every quarter. Direct Response's historical results reflect this pattern and should therefore be viewed on an annual and not quarterly basis.

The Direct Response operations include catalog and online internet sales. This division's strategic plan is to increase internet sales by continuing to incorporate new technologies. For this fiscal second quarter online sales increased to 45% of total Direct Response/E-Commerce sales compared to 36% for the fiscal second quarter of 2007. For the six months ended March 31, 2008, this division processed 1.4 million orders, an increase of over 250 thousand orders compared to the prior like period. NBTY remains the leader in the direct response and e-commerce sectors and continues to increase the number of products available via its catalog and web sites.

NBTY Chairman and CEO, Scott Rudolph, said: "Our continued sales momentum is indicative of NBTY's ability to develop and implement strategic initiatives to enhance our dominant position as the worldwide leader in the nutritional supplement industry. We continue to make investments in our infrastructure and remain well positioned to quickly adapt to meet the challenges of industry segment changes and remain committed to increasing long-term profitability and shareholder value."

ABOUT NBTY

NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company's Nature's Bounty(R) (http://www.NaturesBounty.com), Vitamin World(R) (http://www.VitaminWorld.com), Puritan's Pride(R) (http://www.Puritan.com), Holland & Barrett(R) (http://www.HollandAndBarrett.com), Rexall(R) (http://www.Rexall.com), Sundown(R) (http://www.SundownNutrition.com), MET-Rx(R) (http://www.MetRX.com), Worldwide Sport Nutrition(R) (http://www.SportNutrition.com), American Health(R) (http://www.AmericanHealthUS.com), GNC(UK)(R) (http://www.GNC.co.uk), DeTuinen(R) (http://www.DeTuinen.nl), LeNaturiste(TM) (http://www.LeNaturiste.com), SISU(R) (http://www.SISU.com), Solgar(R) (http://www.Solgar.com), Good 'n' Natural(R) (http://www.goodnnatural.com), Home Health(TM) (http://www.homehealthus.com) and Ester-C(R) (http://www.Ester-C.com) brands.

This release refers to non-GAAP financial measures, such as Adjusted EBITDA. "Adjusted EBITDA" is defined as net income, excluding the aggregate amount of all non-cash losses reducing net income, plus interest, taxes, depreciation and amortization. This non-GAAP financial measure is not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP measure to the comparable GAAP measure is included in the attached financial tables. Management believes the presentation of Adjusted EBITDA is relevant and useful because Adjusted EBITDA is a measurement industry analysts utilize when evaluating NBTY's operating performance. Management also believes Adjusted EBITDA enhances an investor's understanding of NBTY's results of operations because it measures NBTY's operating performance exclusive of interest and non-cash charges for depreciation and amortization. Management also provides this non-GAAP measurement as a way to help investors better understand its core operating performance, enhance comparisons of NBTY's core operating performance from period to period and to allow better comparisons of NBTY's operating performance to that of its competitors.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward-looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.

Contact: Harvey Kamil Carl Hymans

NBTY, Inc. G.S. Schwartz & Co.

President and Chief Financial Officer 212-725-4500

631-200-2020 carlh@schwartz.com

(TABLES FOLLOW)

NBTY, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

(In thousands, except per share amounts)

For the three months

ended March 31,

2008 2007

Net sales $532,518 $508,459

Costs and expenses:

Cost of sales 261,284 239,530

Advertising, promotion and catalog 39,007 34,441

Selling, general and administrative 166,409 151,963

466,700 425,934

Income from operations 65,818 82,525

Other income (expense):

Interest (3,657) (4,154)

Miscellaneous, net 3,786 2,307

129 (1,847)

Income before provision for income taxes 65,947 80,678

Provision for income taxes 21,721 23,324

Net income $44,226 $57,354

Net income per share:

Basic $0.69 $0.85

Diluted $0.67 $0.83

Weighted average common shares outstanding:

Basic 64,102 67,273

Diluted 65,817 69,490

NBTY, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

(In thousands, except per share amounts)


'/>"/>

SOURCE NBTY, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Digirad Corporation Reports Financial Results for First-Quarter 2008
2. Zimmer Holdings, Inc. Reports First Quarter Financial Results
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. Pharmacyclics Reports Third Quarter 2008 Financial Results
5. Symmetry Medical Reports Full Year 2007 Financial Results
6. WellPoint Reports First Quarter 2008 Results
7. NuVasive Reports First Quarter 2008 Financial Results
8. CuraGen Reports First Quarter 2008 Financial Results
9. Albemarle Reports Record Quarterly Net Sales and Operating Results
10. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: